Ascendia

  MARKET NEWS

HCW Biologics Announces Positive Results of Studies of Proprietary Compound & Availability for Commercialization
Oragenics Announces Approval to Initiate Phase 2 Concussion Drug Trial
Alzamend Neuro Initiates First Phase 2 Trial of AL001 “Lithium in Brain” Study
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
ABLi Therapeutics Launches With a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
Veranova Appoints Elizabeth Rebeil as Global Vice President of Supply Chain & Operational Excellence
Polyrizon Targets $3.15B Epilepsy Market With Preclinical Studies for Innovative Rescue Treatment
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated With Intranasal Foralumab
HIV Market to Surpass $32 Billion in 2033
Colorcon & ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical & Nutraceutical Industries

  EXPERT CONTENT & RESOURCES

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.  

ALBA SUCCESS CASE

Container Selection for a Highly Sensitive Drug Product: A Success Story

For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.

How to Choose the Right CDMO for Your Pharmaceutical Project

How to Choose the Right CDMO for Your Pharmaceutical Project

This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.

  FEATURED EDITORIAL

  COMPANY PROFILE

PCI is your world leading CDMO, truly spanning the cycle, connecting development and commercialization, de-risking the supply chain providing integrated drug development, manufacturing and packaging capabilities that increase product speed to market, and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in delivering CDMO services. Leading technology and continued investment enable us to address global outsourcing needs throughout the product lifecycle. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

On Demand Webinar – Emergent CDMO: High-Speed Manufacturing Solutions for Your Viral Vaccine or Therapeutic

On Demand Webinar – Emergent CDMO: High-Speed Manufacturing Solutions for Your Viral Vaccine or Therapeutic

Emergent and groniger partner to present the benefits and features of the INTEGRA® high-speed aseptic fill line with isolator technology for viral vaccines and therapeutics.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 


Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug performance.

Our latest whitepaper delves into the impact of POLYOX™ PEO (Polyethylene Oxide) on drug …

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 21 – Injection Devices
May 28 – Parenteral Contract Manufacturing